{"schema_version":"secwatch.filing_event.v1","accession":"0001826667-25-000007","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.111489+00:00","generated_at":"2026-05-27T15:28:35.667832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025","bullets":["Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.","Q4 operating cash flow (~$5.6M) improved from (~$10.8M) in Q3.","Expects positive full-year EBITDA in 2025 and positive cash flow during H2 2025.","Cash ~$8.5M; expects to qualify for additional $10M debt tranche from OrbiMed in Q1 2025.","Revenue growth guidance for 2025: in excess of 50%."],"urls":{"canonical":"https://secwatch.observer/filing/0001826667-25-000007","json":"https://secwatch.observer/filing/0001826667-25-000007.json","markdown":"https://secwatch.observer/filing/0001826667-25-000007.md","text":"https://secwatch.observer/filing/0001826667-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000007/0001826667-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000007/tlsi-20250123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T15:28:35.667832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}